Monitoring and Managing Hyperphosphatemia

Hyperphosphatemia is the most common AE associated with FGFRi treatments and can impact patient quality of life, but there are treatments and possible diet changes that may help mitigate this AE.

Related Keywords

Chaundra Bishop ,R Katie Kelley ,Caroline Kuhlman ,Lipika Goyal ,Taiho Oncology Inc , ,Taiho Oncology ,Onclive Insights ,Cholangiocarcinoma ,Bile Duct Cancer ,Biliary Tract Cancer ,Intrahepatic Cholangiocarcinoma ,Extrahepatic Cholangiocarcinoma ,Hyperphosphatemia ,Adverse Events ,Fgfri ,Fgfr Inhibitors ,Fgfr Inhibitors Adverse Effects ,Patient Monitoring ,